Article
Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.
Radiology and oncology - 14 Aug 2022
Turnsek Nina, Devjak Rok, Edelbaher Natalija, Osrajnik Ilonka, Unk Mojca, Vidovic Dusanka, Jeric Tina, Janzic Urska
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions. PATIENTS AND METHODS: The REFLECT study (NCT04031898) is a retrospective medical chart review that explored real-life treatment and outcomes of EGFRm...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.